Clinical trials: Maculopathy, Age Related
Choroid Neovascularization, Age-Related Macular Degeneration
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
- Trial name
- NCT00395057
- Testing
- AGN 211745, Ranibizumab 500µg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 138 people
- Sponsor
- Allergan
Dry Eye Syndromes, Age-Related Macular Degeneration
Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the 1st cause of visual impairment after the age of 50. Its most aggressive form, wet AMD, requires regular intravitreal injections (IVI) spaced 4 to 8 weeks apart usually depending on…
- Trial name
- TREDIA (NCT06174181)
- Testing
- Preservative-free ophtalmic lubricant emulsion, Routine treatment
- Where
- 2 sites in France
- Volunteers
- 42 people
- Sponsor
- Direction Centrale du Service de Santé des Armées
AMD - Age-Related Macular Degeneration
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular…
- Trial name
- NCT07418177
- Testing
- hiPSC-RPEs
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Geographic Atrophy
Evolution and Risk Factors Associated With Geographic Atrophy Progression
Age-related macular degeneration is one of the leading causes of blindness worldwide. The factors that induce the progression of geographic atrophy, the advanced form of dry age-related macular degeneration, remain poorly…
- Trial name
- GAIN (NCT01694095)
- Where
- Spain
- Volunteers
- 96 people
- Sponsor
- Institut de la Macula y la Retina
Diabetic Retinopathy, Glaucoma
AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care
Background: Diabetic retinopathy (DR) is one of the most important causes of blindness worldwide, especially in developed countries.
- Conditions
- Diabetic Retinopathy, Glaucoma, Age-Related Macular Degeneration, Choroidal Nevus
- Trial name
- NCT04132401
- Testing
- algorithm
- Where
- Spain
- Volunteers
- 902 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Age Related Macular Degeneration, Choroidal Neovascularization
Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)
To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence…
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema
- Trial name
- NCT00729846
- Testing
- Bevacizumab, verteporfin photodynamic therapy reduced fluence, verteporfin photodynamic therapy standardfluence
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- California Retina Consultants
Age-Related Macular Degeneration, Retinal Function
Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
Multifocal-electroretinoram (ERG) and microperimetry are objective criteria to asses retinal function. No information besides visual acuity exist for the development of retinal function during the course of wet AMD during therapy…
- Trial name
- LucERG (NCT01269151)
- Testing
- Lucentis (Ranibizumab)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University of Luebeck
Age-Related Macular Degeneration
Assessing the Quality of Life and Social Support in Age-Related Macular Degeneration Patients
The aim of this study is to evaluate the quality of life of AMD patients related to vision using the short version of the National Eye Institute Visual Function Questionnaire (NEI-VFQ-25), patients' social support, and their…
- Trial name
- NCT05427994
- Testing
- National Eye Institute Visual Function Questionnaire
- Where
- 2 sites in Kazakhstan
- Volunteers
- 458 people
- Sponsor
- Asfendiyarov Kazakh National Medical University
Age-Related Macular Degeneration
Study EvAluating Genotypes While Using Lucentis 2
The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms
- Trial name
- SEAGUL2 (NCT01464723)
- Testing
- Ranibizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Diego
Geographic Atrophy, Age-Related Macular Degeneration
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD.
- Trial name
- NCT07160179
- Testing
- ABBV-6628, SYFOVRE
- Where
- 5 sites in United States
- Volunteers
- 66 people
- Sponsor
- AbbVie
Macular Degeneration
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
- Trial name
- NCT00065728
- Testing
- Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Age-related Macular Degeneration
Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration
The global aim of this project is to expand the knowledge on the multifactorial pathogenesis of AMD. In addition to age, the multifactorial pathogenesis of AMD includes environmental and genetic risk factors.
- Trial name
- AMDMetab (NCT04241536)
- Testing
- Blood draw and urine collection
- Where
- Portugal
- Volunteers
- 295 people, healthy volunteers welcome
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Neovascular Age Related Macular Degeneration
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A study to use in home technology to reduce the burden of in office visits and injections.
- Trial name
- Liberty (NCT01863199)
- Testing
- Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Retinal Consultants of Arizona
Age-related Macular Degeneration
QA102 Phase 1 Study in Healthy Young and Older Adult Subjects
This will be a double masked, randomized, placebo controlled, single and multiple oral dose study conducted in 3 parts. The safety and tolerability of single and multiple ascending oral doses of QA102 in healthy young and older…
- Trial name
- NCT04894071
- Testing
- QA102
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Smilebiotek Zhuhai Limited
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Multicenter, randomized, masked, controlled study of the safety and effectiveness of intravitreally administered ONS-5010.
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT06190093
- Testing
- bevacizumab, ranibizumab
- Where
- 61 sites in United States
- Volunteers
- 400 people
- Sponsor
- Outlook Therapeutics, Inc.
Age-Related Macular Degeneration, Diabetic Retinopathy
Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations
In this study, participants will be imaged using two Optical Coherence Tomography (OCT) devices: device N, a standard conventional OCT device with an invention (comfortable chin and forehead rest that can be adjusted to fit each…
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Central Serous Chorioretinopathy, Glaucoma
- Trial name
- NCT05686421
- Testing
- OCT Imaging Using Device N, OCT Imaging Using Device C
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Macular Degeneration Choroidal Neovascularization
Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC
To evaluate the activity of neovascular macula degeneretion as assessed by SD-OCTand OCT-A using a split-person study design and deep-learning quantification.
- Trial name
- OCTA (NCT05969418)
- Testing
- Diagnostic test: using artificial intelligence to evaluate the changes OCT and OCTA parameter
- Where
- Italy
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Federico II University
Neovascular Age-related Macular Degeneration
Defining Disease Activity in Neovascular AMD With Optical Coherence Tomography Angiography
The purpose of this study is to be able to describe optical coherence angiography (OCTA) patterns of disease activity and quiescence in eyes that have received treatment.
- Trial name
- DANA (NCT03909425)
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Choroidal Neovascularization, Age-Related Macular Degeneration
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
- Trial name
- NCT00470678
- Testing
- ranibizumab
- Where
- 6 sites in South Korea, Taiwan
- Volunteers
- 95 people
- Sponsor
- Novartis
AMD - Age-Related Macular Degeneration
Photobiomodulation Laser for Reticular Pseudodrusen in Age-Related Macular Degeneration
This study evaluates whether a low-energy laser treatment called photobiomodulation (PBM) can improve visual function and retinal structure in patients with age-related macular degeneration (AMD) who have reticular pseudodrusen.
- Trial name
- PBM in iAMD (NCT07554690)
- Testing
- Photobiomodulation Therapy
- Where
- Italy
- Volunteers
- 67 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.